巴曲酶治疗急性脑梗死疗效观察  

Clinical Research on Batroxobin in Treatment of Patients with Acute Cerebral Infarction

作　　者：冯慧琼[1] 王颖慧[1] 

机构地区：[1]包头医学院第一附属医院,内蒙古包头014010

出　　处：《包头医学院学报》2011年第4期45-46,共2页Journal of Baotou Medical College

摘　　要：目的：探讨巴曲酶治疗急性脑梗死的临床疗效。方法：152例急性脑梗死患者（起病6~72 h内）随机分成巴曲酶治疗组和常规治疗对照组,治疗前后进行血浆纤维蛋白原（FIB）测定和神经功能缺损评分。结果：观察组经治疗后FIB水平下降非常显著（P〈0.01）,神经功能缺损评分降低显著（P〈0.05）;对照组治疗前后血纤维蛋白原、神经功能缺损评分无显著变化（P〉0.05）。结论：距起病6~72 h的巴曲酶早期使用仍可显著改善急性脑梗死临床症状。Objective： To investigate the clinical effects of batroxobin on the treatment of patients with acute cerebral infarction （ACI）. Methods： One hundred and fifty two cases with ACI were collected, and were randomly divided into batroxobin treatment group and control group. The level of plasma fibrinogen and neurological deficit score were determined in all patients before and after the treatment. Results ： The level of plasma fibrinogen and neurological deficit score in patients were significantly decreased after treatment with batroxobin. Conclusion ： Early use of batroxobin can significantly improve the clinical symptoms of patients with ACI in 6 - 72 hours from the onset of disease.

关 键 词：急性脑梗死 巴曲酶 纤维蛋白原 

分 类 号：R743.3[医药卫生—神经病学与精神病学]